HISTORY
Initial Public Offering



On August 10, 2005, we consummated an initial public offering of 4.6 million shares of our common stock at $12.00 per share, which includes the underwriters exercise of their over-allotment option, on August 9, 2005, to purchase 600,000 shares of our common stock of which 450,000 shares were sold by selling shareholders and 150,000 shares were sold by us. We did not receive any proceeds from the sale of the 450,000 shares of common stock that were sold by selling shareholders. These share amounts reflect a 1-for-3.8 reverse split of our capital stock that was effected on July 27, 2005. Proceeds to us from the offering, after deducting underwriting discounts and commissions but before expenses, were $46.3 million. Expenses are estimated to be approximately $3.25 million.



15

AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.

Hey Wobblenuts and Jackie Scan I want to show you something....

Medical Breakthrough Wound Stasis Technology

ATRC and EPGL could possibly go hand in hand here...
Merry Christmas 2012

Merry Chirstmas 2012, friends.

Any talks involving ATRC and soon to be sub penny wonder EPGL?



Are they hinting at something here?


1)"ATRC fully SEC reporting financials are available at OTCMARKETS for EPGL investors to see as an example of where EPGL management is headed."

2)"EPGL initiating R&D on 4 new medical devices before end of 2012."

3)"Property and equipment, net 0"

~ Monday! $ATRC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ATRC ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ATRC&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ATRC&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ATRC
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ATRC#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ATRC+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ATRC
Finviz: http://finviz.com/quote.ashx?t=ATRC
~ BusyStock: http://busystock.com/i.php?s=ATRC&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ATRC >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

http://www.google.com/finance?q=ATRC